1601. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

1602. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group

1603. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece

1604. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA)

1605. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis

1606. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression

1607. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

1608. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer

1609. Lymphoepithelioma-like carcinoma of the bladder

1610. Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers

1611. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience

1612. Plasmacytoid transitional cell carcinoma of the bladder

1613. Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS: 2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group

1614. Laparoscopy in the evaluation of women with unexplained ascites: an invaluable diagnostic tool

1615. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer

1616. Intravesical interferon alfa-2b administration in the treatment of superficial bladder tumors

1617. Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.

1618. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy

1619. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

1620. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients≥ 65 years old with relapsed or refractory multiple myeloma